The α-diversity analysis revealed an elevated number of observed species in the baseline gut microbiome of responders, although the difference did not reach statistical significance between the groups (Fig. 6A ).
← all excerpts
Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial.
1
—
—